ClinicalTrials.gg
CompletedNCT04112446Updated Nov 13, 2019

Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects

A Phase 1 interventional study of Saroglitazar magnesium in Healthy, sponsored by Zydus Therapeutics Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This will be a Phase I, open-label, nonrandomized, single-dose study in healthy male subjects.

Read the detailed description

Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the dose administration. Subjects will be admitted into the Clinical Research Unit (CRU) on Day -1 and be confined to the CRU until at least Day 8. On Day 1, subjects will receive a single oral dose of [14C]-saroglitazar magnesium. Subjects will be discharged if the following discharge criteria are met: plasma radioactivity levels below the limit of quantitation for 2 consecutive collections and ≥ 90% mass balance recovery, or ≤ 1% of the total radioactive dose is recovered in combined excreta (urine and feces) in 3 consecutive 24-hour periods in which both are collected. If discharge criteria are not met by Day 8, subjects will remain in the CRU up to Day 12.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males, of any race, between 18 and 55 years of age, inclusive.
  2. (BMI) between 18.0 and 32.0 kg/m2, inclusive.
  3. In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, and clinical laboratory evaluations at Screening and/or Check-in as assessed by the Investigator (or designee).
  4. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  5. History of a minimum of 1 bowel movement per day.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
  3. Known hypersensitivity to either saroglitazar magnesium or other PPAR agonists, and/or the in the saroglitazar magnesium formulation.
  4. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed). History of cholecystectomy will not be allowed.
  5. Subjects with congenital nonhemolytic hyperbilirubinemia (eg, suspicion of Gilbert's syndrome based on total and direct ).
  6. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in.
  7. Alcohol consumption of > 14 units per week. One unit of alcohol equals 12 oz (360 mL) of beer, 1½ oz (45 mL) of liquor, or 5 oz (150 mL) of wine.
  8. Positive urine drug screen at Screening or positive alcohol breath test result or positive urine drug screen at Check-in.
  9. Positive hepatitis panel and/or positive test ( Appendix 2).
  10. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 90 days prior to dosing or 5 times the t1/2 (whichever is longer).
  11. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  12. Use or intend to use any prescription medications/products within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  13. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  14. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  15. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in, or positive cotinine at Screening or Check-in.
  16. Receipt of blood products within 2 months prior to Check-in.
  17. Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening.
  18. Poor peripheral venous access.
  19. Have previously completed or withdrawn from this study or any other study investigating saroglitazar magnesium, and have previously received the investigational product.
  20. Subjects with exposure to significant diagnostic or therapeutic radiation (eg, serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in.
  21. Subjects who have participated in a radiolabeled drug study where exposures are known to the Investigator within the previous 4 months prior to admission to the clinic for this study or participated in a radiolabeled drug study where exposures are not known to the Investigator within the previous 6 months prior to admission to the clinic for this study. The total 12-month exposure from this study and a maximum of 2 other previous radiolabeled studies within 4 to 12 months prior to this study will be within the Code of Federal Regulations (CFR) recommended levels considered safe, per United States (US) Title 21 CFR 361.1: less than 5,000 mrem whole-body annual exposure with consideration given to the half-lives of the previous radiolabeled study drugs received.
  22. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Study Treatment

    4 mg \[14C\]-saroglitazar magnesium (approximately 100 μCi) oral suspension

    Drug: Saroglitazar magnesium

Interventions

  • On Day 1, subjects will receive a single oral dose of \[14C\]-saroglitazar magnesium

    Also known as: not any

06

What researchers measure

Primary outcomes

  1. AUC from time zero to infinity (AUC0-∞)

    Area under the time curve from time zero to infinity will be calculated for saroglitazar and saroglitazar sulfoxide in plasma, and total radioactivity in whole blood and plasma

    Time frame: At predose to maximum up to Day 12

  2. AUC from time zero to the last quantifiable concentration (AUC0-t) administration of [14C]-saroglitazar magnesium

    Area under the time curve from time zero to the last quantifiable concentration will be calculated for saroglitazar and saroglitazar sulfoxide in plasma, and total radioactivity in whole blood and plasma

    Time frame: At predose to maximum up to Day 12

  3. Cmax

    Maximum observed concentration will be calculated for saroglitazar and saroglitazar sulfoxide in plasma, and total radioactivity in whole blood and plasma

    Time frame: At predose to maximum up to Day 12

  4. Tmax

    Time to reach maximum observed concentration will be calculated for saroglitazar and saroglitazar sulfoxide in plasma, and total radioactivity in whole blood and plasma

    Time frame: At predose to maximum up to Day 12

  5. t1/2

    Apparent terminal elimination half-life will be calculated for saroglitazar and saroglitazar sulfoxide in plasma, and total radioactivity in whole blood and plasma

    Time frame: At predose to maximum up to Day 12

  6. Apparent total clearance (CL/F)

    The apparent total clearance (CL/F) will be determined for saroglitazar

    Time frame: At predose to maximum up to Day 12

  7. Apparent volume of distribution (Vz/F) during the terminal elimination phase

    The Apparent volume of distribution (Vz/F) during the terminal elimination phase will be determined for saroglitazar

    Time frame: At predose to maximum up to Day 12

  8. AUC0-∞ of plasma saroglitazar relative to AUC0-∞ of plasma total radioactivity (AUC0-∞ Plasma saroglitazar/Total Radioactivity Ratio)

    AUC0-∞ of plasma saroglitazar relative to AUC0-∞ of plasma total radioactivity (AUC0-∞ Plasma saroglitazar/Total Radioactivity Ratio) will be calculated

    Time frame: At predose to maximum up to Day 12

  9. AUC0-∞ of whole blood total radioactivity to AUC0-∞ of plasma total radioactivity (AUC0 ∞ Blood/Plasma Ratio)

    AUC0-∞ of whole blood total radioactivity to AUC0-∞ of plasma total radioactivity (AUC0 ∞ Blood/Plasma Ratio) will be calculated

    Time frame: At predose to maximum up to Day 12

  10. Mean residence time

    Mean residence time for saroglitazar and saroglitazar sulfoxide will be calculated

    Time frame: At predose to maximum up to Day 12

  11. Total radioactivity amount excreted in urine and feces

    Amount of radioactivity excreted in urine and Feces will be calculated.

    Time frame: At predose to maximum up to Day 12

  12. Percentage radioactivity excreted in urine and feces

    Percentage radioactivity excreted in urine and Feces will be calculated.

    Time frame: At predose to maximum up to Day 12

  13. Renal clearance (CLR)

    Renal clearance for saroglitazar and saroglitazar sulfoxide will be determined

    Time frame: At predose to maximum up to Day 12

Secondary outcomes

  1. Metabolic profile/ identifications of metabolites and probable structure elucidation for saroglitazar in plasma, urine, and feces

    Metabolic profile/ identifications of metabolites and probable structure elucidation for saroglitazar in different matrices like plasma, urine, and feces will be performed and reported

    Time frame: Maximum up to Day 12

  2. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    Incidence and severity of AEs as a measure of safety and tolerability will be measured and reported

    Time frame: Maximum up to Day 12

Other outcomes

  1. Amount of Saroglitazar excreted in feces

    Amount of Saroglitazar in Fecal samples will be calculated.

    Time frame: At predose to maximum up to Day 12

  2. Percentage of Saroglitazar excreted in feces

    Percentage of Saroglitazar excreted in Fecal samples will be calculated.

    Time frame: At predose to maximum up to Day 12

07

Study locations

1 site
  • Covance Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Oct 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2019
First posted
Oct 2, 2019
StartActual
Sep 20, 2019
Primary completionActual
Oct 29, 2019
CompletionActual
Oct 29, 2019
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04112446
Responsible party
Sponsor
First posted
Oct 2, 2019
Start date
Sep 20, 2019
Primary completion
Oct 29, 2019
Completion
Oct 29, 2019
Last update
Nov 13, 2019

Study contacts

John E. Blanchard, MD
principal investigator · Covance

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion